Search

Introduction: C-reactive protein (CRP) is an inflammatory mediator that could be elevated in malignant conditions. The aim of our study is to assess the relationship between CRP and response to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: This is a retrospective study including 142 patients with advanced NSCLC (stage IIIB and IV) diagnosed between January 2005 and January 2013. Prior to chemotherapy, a CRP level higher than 10mg/l is related to cancer if a decrease of 50% is noted after two cycles of chemotherapy. An initial CRP level that decreases by 50% after antibiotics is related to an infection. Results: The average age was 60 years. The median level of CRP was 47.9 mg/l. Only 16.9% of patients had a CRP level lower than 10mg/l. Correlations between CRP level and BMI (r=-0.34, p=0.0001), tumor size (r=0.25, p=0.039), smoking (r=0.17, p=0.04) and serum albumin level (r=-0.66; p Conclusion: CRP could be taken into account with RECIST criteria to evaluate the response to chemotherapy in advanced NSCLC.

Introduction: Brain metastases (BM) are a common complication for patients with non-small-cell lung cancer (NSCLC) and a significant cause of morbidity and mortality. The aim of this study was to evaluate the management of BM for patients with NSCLC. Methods: This was a retrospective study including 100 patients with BM of NSCLC hospitalized in our service between January 2009 and December 2015. Results: Median age was 57 years, 94 patients were male. Ninety patients (90%) were smokers. The performans status was Conclusion: Survival remains poor for patients with NSCLC and BM. However, aggressive therapy of both the lung primary tumour and the BM may provide a survival advantage.